Sanofi: Crédit Suisse confirms buy rating
(CercleFinance.com) - Sanofi has organised the third of its four R&D events, focusing on Dupixent.
The group's chairman and CEO points out that Dupixent already offers excellent efficacy and safety and could maintain its standard of care position.
Credit Suisse believes that the group is confident in its ability to maintain its leadship in atopic dermatitis (AD) and other type 2 inflammatory diseases.
"Sanofi reiterated their >E10b/$11.4b peak without COPD. CS forecast potential peak sales of >$13b," analysts say.
Crédit Suisse confirms its Outperform rating on the share, along with a target price of 105 eurors. "Sanofi remains a top pick in the sector based on current low valuation and an expected improvement in returns as new management focusses both R&D and marketing resources better," the broker says.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The group's chairman and CEO points out that Dupixent already offers excellent efficacy and safety and could maintain its standard of care position.
Credit Suisse believes that the group is confident in its ability to maintain its leadship in atopic dermatitis (AD) and other type 2 inflammatory diseases.
"Sanofi reiterated their >E10b/$11.4b peak without COPD. CS forecast potential peak sales of >$13b," analysts say.
Crédit Suisse confirms its Outperform rating on the share, along with a target price of 105 eurors. "Sanofi remains a top pick in the sector based on current low valuation and an expected improvement in returns as new management focusses both R&D and marketing resources better," the broker says.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.